Pharma feed
N
Novartis is entering one of its most productive R&D periods, with 25 potential blockbusters in the pipeline, including five new molecules which reach the market in the next two years. That was the message delivered by CEO Vas Narasimhan at the company’s annual R&D update, as Novartis showcased a pipeline with more than 200 projects in clinical development, and 60 major submissions planned in before the end of 2021.
N
Following the signing of an agreement between AbbVie and the pan-Canadian Pharmaceutical Alliance (pCPA), Ontario is the first province to reimburse VENCLEXTA. VENCLEXTA is the first and only BCL-2 inhibitor to be approved in Canada.
N
2019-2025 Global Pet Medication Market Research Report: The report presents an in-depth assessment of the Pet Medication including enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies.
N
Eli Lilly has announced the market launch of a half-price, generic version of its Humalog insulin. Called Insulin Lispro Injection, the product is available in a vial or within a KwikPen. Insulin Lispro can be substituted for Humalog as they contain the same insulin.
N
A new market study, titled “Global Psoriasis Drug Market Insights, Forecast to 2025”, has been featured on WiseGuyReports. Psoriasis Drug Market Psoriasis is a long-lasting autoimmune disease which is characterized by patches of abnormal skin. The global Psoriasis Drug market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
TARRYTOWN, N.Y., May 23, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the Goldman Sachs 40th Annual Global Healthcare Conference at 9:20 a.m. Pacific Time ( 12:20 p.m. Eastern Time ) on Tuesday, June 11, 2019 .
N
GlaxoSmithKline announced Thursday that China's National Medical Products Administration has approved Shingrix following an expedited review for the prevention of shingles in adults aged 50 years or older.
All fields are required. Please make sure all fields are completed.
N
Merck & Co. acquires Peloton Merck & Co. swooped in to acquire Peloton Therapeutics this week, heading off a planned IPO by the biotech company. The upfront cost is $1 billion. The deal provides Merck access to PT2977, an oral therapy with a novel mechanism of action currently moving into late-stage development for renal cancer.
N
Law360, Oakland, Calif. (May 23, 2019, 8:18 PM EDT) -- A California judge on Thursday admonished a microbiologist testifying for Johnson & Johnson and Colgate-Palmolive in a jury trial over claims their talcum powder products contained cancer-causing asbestos, saying she “clearly violated” his pretrial rulings by raising an off-limits topic, but declined to sanction the companies.
N
Advisors Preferred Llc decreased its stake in Pfizer Inc (PFE) by 51.33% based on its latest 2018Q4 regulatory filing with the SEC. Advisors Preferred Llc sold 8,240 shares as the company’s stock declined 4.08% while stock markets rallied.
N
Snyder Capital Management LP increased its stake in Coherent Inc. (COHR) by 8.38% based on its latest 2018Q4 regulatory filing with the SEC. Snyder Capital Management LP bought 8,557 shares as the company’s stock rose 1.83% with the market.
N
Recently for those that trade M&A stocks it has been a case of arbageddon. So many current deals have hit potholes in one way or another. Spark Therapeutics (ONCE) has filed and then refiled their respective pre-merger notification and report forms to federal regulators an unusually high three times.
Vas Narasimhan has been CEO at Novartis for just a little more than a year since his promotion from development chief. And in today’s investor meeting, after spinning off Alcon and putting the wheels in motion to do a makeover at the suffering generics wing Sandoz, the spotlight is being turned straight at his prized possession: the pipeline.
N
Piotr Swat / Shutterstock.com Verily, which is a subsidiary of Google’s parent company Alphabet, yesterday announced that it had partnered with Novartis, Otsuka, Pfizer, and Sanofi in efforts to develop digitally-innovative clinical research programmes. Alphabet’s Verily, which was launched in 2015, uses health data to create interventions that prevent and manage diseases.
N
Merck & Co. acquires Peloton Merck & Co. swooped in to acquire Peloton Therapeutics this week, heading off a planned IPO by the biotech company. The upfront cost is $1 billion. The deal provides Merck access to PT2977, an oral therapy with a novel mechanism of action currently moving into late-stage development for renal cancer.
N
To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.
N
The Global Metabolite Chemistry Reagents Market report includes a scrupulous analysis of the Metabolite Chemistry Reagents market in the forecasted period. It also assesses the Metabolite Chemistry Reagents market in terms of topography, technology, and consumers.
N
Finasteride is a prescription drug in tablet form. Finasteride Market Report by Material, Application, and Geography – Global Forecast to 2024 is a professional and in-depth research report on the world’s major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China).
N
Paradigm Financial Partners LLC acquired a new stake in shares of Merck & Co., Inc. (NYSE:MRK) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 26,328 shares of the company’s stock, valued at approximately $2,012,000.
N
As per a new research report titled Global External Nasal Dilator Market Professional Survey Report 2019, the forenamed market delivers extensive analysis of market trends and shares. It’s an insightful data for all the players operating in the market.
N
The U.S. Food and Drug Administration approved AveXis’ Zolgensma, the first gene therapy to treat children less than two years of age with the most severe form of spinal muscular atrophy, and a leading genetic cause of infant death.
N
New Mexico Educational Retirement Board reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 228,343 shares of the company’s stock after selling 10,800 shares during the quarter.
N
Surging sales of the cancer immunotherapy medication and vaccines Keytruda led during the quarter to a quadrupling of profit at Merck because it blew past Wall Street expectations. Sales of Keytruda jumped 55% to $2.27 billion, about one-quarter of overall revenue.
N
TIAA FSB grew its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 2.6% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 122,050 shares of the biopharmaceutical company’s stock after acquiring an additional 3,134 shares during the quarter.